Genetic Technologies Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Genetic Technologies.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	20.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Genetic Technologies Limited's (ASX:GTG) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 15

Should You Take Comfort From Insider Transactions At Genetic Technologies Limited (ASX:GTG)?

Dec 17

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Genetic Technologies no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

ASX:GTG - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	10	-12	-10	-10	N/A
3/31/2024	10	-12	-9	-9	N/A
12/31/2023	10	-13	-8	-8	N/A
9/30/2023	10	-12	-9	-9	N/A
6/30/2023	10	-12	-10	-10	N/A
3/31/2023	11	-10	-9	-9	N/A
12/31/2022	11	-9	-8	-8	N/A
9/30/2022	10	-8	-7	-7	N/A
6/30/2022	9	-7	-6	-6	N/A
3/31/2022	7	-7	-6	-6	N/A
12/31/2021	5	-7	-7	-7	N/A
9/30/2021	3	-7	-7	-6	N/A
6/30/2021	1	-7	-7	-6	N/A
3/31/2021	2	-7	-7	-6	N/A
12/31/2020	0	-7	-7	-7	N/A
9/30/2020	0	-7	-6	-6	N/A
6/30/2020	1	-6	-6	-6	N/A
3/31/2020	0	-6	-6	-5	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-6	-6	-6	N/A
6/30/2019	0	-6	-6	-6	N/A
3/31/2019	0	-6	-6	-6	N/A
12/31/2018	0	-5	-6	-6	N/A
9/30/2018	0	-5	-6	-6	N/A
6/30/2018	0	-5	-6	-6	N/A
3/31/2018	0	-7	N/A	-6	N/A
12/31/2017	0	-8	N/A	-6	N/A
9/30/2017	0	-8	N/A	-7	N/A
6/30/2017	1	-8	N/A	-7	N/A
3/31/2017	1	-8	N/A	-7	N/A
12/31/2016	1	-8	N/A	-7	N/A
9/30/2016	1	-8	N/A	-7	N/A
6/30/2016	1	-8	N/A	-8	N/A
3/31/2016	1	-8	N/A	-8	N/A
12/31/2015	1	-8	N/A	-8	N/A
9/30/2015	2	-9	N/A	-9	N/A
6/30/2015	2	-9	N/A	-10	N/A
3/31/2015	3	-9	N/A	-11	N/A
12/31/2014	4	-10	N/A	-12	N/A
9/30/2014	4	-10	N/A	-11	N/A
6/30/2014	5	-10	N/A	-11	N/A
3/31/2014	4	-10	N/A	-10	N/A
12/31/2013	4	-11	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de GTG es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de GTG crezcan más rápidamente que el mercado Australian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de GTG crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de GTG crezcan más rápidamente que el mercado de Australian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de GTG crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de GTG se prevé que sea elevada dentro de 3 años.

Genetic Technologies Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

New major risk - Revenue and earnings growth

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Independent Non-Executive Chairman recently bought AU$80k worth of stock

New major risk - Financial position

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited's (ASX:GTG) CEO Will Probably Find It Hard To See A Huge Raise This Year

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Should You Take Comfort From Insider Transactions At Genetic Technologies Limited (ASX:GTG)?

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Receives Delisting Notification Letter from Nasdaq

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento